Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Evaluation of the Biological Behavior of a Gold Nanocore-Encapsulated Human Serum Albumin Nanoparticle (Au@HSANP) in a CT-26 Tumor/Ascites Mouse Model after Intravenous/Intraperitoneal Administration.

Chen CC, Li JJ, Guo NH, Chang DY, Wang CY, Chen JT, Lin WJ, Chi KH, Lee YJ, Liu RS, Chen CL, Wang HE.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E217. doi: 10.3390/ijms20010217.

2.

Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.

Hsieh YC, Wang HE, Lin WW, Roffler SR, Cheng TC, Su YC, Li JJ, Chen CC, Huang CH, Chen BM, Wang JY, Cheng TL, Chen FM.

Theranostics. 2018 May 9;8(11):3164-3175. doi: 10.7150/thno.22164. eCollection 2018.

3.

Quantitative Measurement of the Thyroid Uptake Function of Mouse by Cerenkov Luminescence Imaging.

Ke CC, He ZM, Hsieh YJ, Huang CW, Li JJ, Hwu L, Chen YA, Yang BH, Chang CW, Huang WS, Liu RS.

Sci Rep. 2017 Jul 18;7(1):5717. doi: 10.1038/s41598-017-05516-5.

4.

Synthesis and biological evaluation of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy)benzothiazole ([18F]FEDBT) for PET imaging of breast cancer.

Li GY, Vaulina DD, Li JJ, Fedorova OS, Wang HE, Liu RS, Krasikova RN, Chen CL.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3460-3463. doi: 10.1016/j.bmcl.2017.05.079. Epub 2017 May 26.

PMID:
28619538
5.

Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles.

Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH, Cheng TL.

Sci Rep. 2016 Dec 19;6:39119. doi: 10.1038/srep39119.

6.

Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET.

Wu CY, Tang JH, Chan PC, Li JJ, Lin MH, Shen CC, Liu RS, Wang HE.

Mol Imaging Biol. 2017 Jun;19(3):408-420. doi: 10.1007/s11307-016-1005-2.

PMID:
27730471
7.

Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.

Li JJ, Chang SF, Liau II, Chan PC, Liu RS, Yen SH, Wang HE, Chang CA.

J Biomed Sci. 2016 Jan 22;23:15. doi: 10.1186/s12929-016-0227-6.

8.

Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System.

Li JJ, Lan KL, Chang SF, Chen YF, Tsai WC, Chiang PH, Lin MH, Fischer WB, Shih YS, Yen SH, Liu RS, Tsay YG, Wang HE, Chang CA.

Bioconjug Chem. 2015 Dec 16;26(12):2481-96. doi: 10.1021/acs.bioconjchem.5b00509. Epub 2015 Nov 24.

PMID:
26525951
9.

Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy.

Yang FY, Chang WY, Li JJ, Wang HE, Chen JC, Chang CW.

J Nucl Med. 2014 Apr;55(4):616-21. doi: 10.2967/jnumed.113.125716. Epub 2014 Feb 13.

10.

Tumor burden talks in cancer treatment with PEGylated liposomal drugs.

Lin YY, Kao HW, Li JJ, Hwang JJ, Tseng YL, Lin WJ, Lin MH, Ting G, Wang HE.

PLoS One. 2013 May 10;8(5):e63078. doi: 10.1371/journal.pone.0063078. Print 2013.

11.

Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound.

Yang FY, Wang HE, Liu RS, Teng MC, Li JJ, Lu M, Wei MC, Wong TT.

PLoS One. 2012;7(9):e45468. doi: 10.1371/journal.pone.0045468. Epub 2012 Sep 18.

12.

Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.

Lin YY, Chang CH, Li JJ, Stabin MG, Chang YJ, Chen LC, Lin MH, Tseng YL, Lin WJ, Lee TW, Ting G, Chang CA, Chen FD, Wang HE.

Cancer Biother Radiopharm. 2011 Jun;26(3):373-80. doi: 10.1089/cbr.2010.0906. Epub 2011 Jun 28.

13.

Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model.

Lin YY, Li JJ, Chang CH, Lu YC, Hwang JJ, Tseng YL, Lin WJ, Ting G, Wang HE.

Cancer Biother Radiopharm. 2009 Aug;24(4):453-60. doi: 10.1089/cbr.2008.0572.

PMID:
19694580
14.

Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways.

Lin SJ, Chang C, Ng AK, Wang SH, Li JJ, Hu CP.

Apoptosis. 2007 Sep;12(9):1659-70.

PMID:
17624592
15.

Proteomics analysis of a novel compound: cyclic RGD in breast carcinoma cell line MCF-7.

Juan HF, Wang IH, Huang TC, Li JJ, Chen ST, Huang HC.

Proteomics. 2006 May;6(10):2991-3000.

PMID:
16619296

Supplemental Content

Loading ...
Support Center